Charles Schwab
ORIC icon

Charles Schwab’s Oric Pharmaceuticals ORIC Stock Holding History

Charles Schwab’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.34M Buy
677,823
+72,786
+12% +$660K ﹤0.01% 2299
2026
Q1 		$7.67M Sell
605,037
-16,049
-3% -$182K ﹤0.01% 2219
2025
Q4 		$5.08M Buy
621,086
+17,879
+3% +$206K ﹤0.01% 2449
2025
Q3 		$7.24M Buy
603,207
+220,818
+58% +$2.32M ﹤0.01% 2273
2025
Q2 		$3.88M Sell
382,389
-26,116
-6% -$175K ﹤0.01% 2435
2025
Q1 		$2.28M Sell
408,505
-9,450
-2% -$82.6K ﹤0.01% 2567
2024
Q4 		$3.37M Buy
417,955
+7,726
+2% +$70.9K ﹤0.01% 2518
2024
Q3 		$4.2M Buy
410,229
+247,863
+153% +$2.45M ﹤0.01% 2458
2024
Q2 		$1.15M Buy
162,366
+57,822
+55% +$518K ﹤0.01% 2878
2024
Q1 		$1.44M Sell
104,544
-2,057
-2% -$24.4K ﹤0.01% 2686
2023
Q4 		$981K Buy
106,601
+719
+0.7% +$5.2K ﹤0.01% 2841
2023
Q3 		$641K Hold
105,882
– – ﹤0.01% 2954
2023
Q2 		$822K Buy
105,882
+89,229
+536% +$507K ﹤0.01% 2832
2023
Q1 		$94.9K Hold
16,653
– – ﹤0.01% 3256
2022
Q4 		$98.1K Hold
16,653
– – ﹤0.01% 3263
2022
Q3 		$54K Sell
16,653
-127,664
-88% -$511K ﹤0.01% 3316
2022
Q2 		$647K Sell
144,317
-71,196
-33% -$284K ﹤0.01% 2966
2022
Q1 		$1.15M Sell
215,513
-8,918
-4% -$80.3K ﹤0.01% 2799
2021
Q4 		$3.3M Buy
224,431
+4,776
+2% +$74.5K ﹤0.01% 2548
2021
Q3 		$4.59M Buy
219,655
+88,840
+68% +$1.8M ﹤0.01% 2417
2021
Q2 		$2.31M Buy
130,815
+16,312
+14% +$357K ﹤0.01% 2666
2021
Q1 		$2.81M Buy
114,503
+4,790
+4% +$151K ﹤0.01% 2551
2020
Q4 		$3.71M Buy
109,713
+56,837
+107% +$1.63M ﹤0.01% 2361
2020
Q3 		$1.32M Sell
52,876
-846
-2% -$20.1K ﹤0.01% 2617
2020
Q2 		$1.81M Buy
+53,722
New +$1.71M ﹤0.01% 2459

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab's ORIC Position: Q2 2026 in Review

Charles Schwab increased its Oric Pharmaceuticals (ORIC) stake by 12% in Q2 2026, buying an estimated $660K and bringing the position to 677,823 shares worth $7.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2299.

Charles Schwab first reported a position in ORIC in Q2 2020 and has held it in 25 quarters since. The position peaked at $7.67M in Q1 2026. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Charles Schwab held 677,823 shares of Oric Pharmaceuticals worth $7.34M as of Q2 2026.
  • Charles Schwab bought 72,786 Oric Pharmaceuticals shares in Q2 2026, an estimated $660K.
  • Oric Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2299 holding.
  • Charles Schwab first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Charles Schwab's Oric Pharmaceuticals position peaked at $7.67M in Q1 2026.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.